References

• 1. 1)
     • 37. Wolff, H., Müller, H.: ‘Structure of the NH stretching vibrational band of pyrazole. Multiple resonance of substances forming strong H or D bonds’, J. Spectrochimica Acta. Part A., 1976, 3, pp. 581–585, doi:10.1016/0584-8539(76)80120-1.
  2. 2)
     • 22. Asiman, D., Mohammed, T.A., Selvaraj, R.: ‘Mesoporous magnetite nanoparticles synthesis using the Peltophorum pterocarpum pod extract, their antibacterial efficacy against pathogens and ability to remove a pollutant dye’, J. Mol. Struct., 2019, 1178, pp. 268–273 (doi: 10.1016/j.molstruc.2018.10.042).
  3. 3)
     • 15. Zhang, W.-M., Xing, M., Zhao, T.-T., et al: ‘Synthesis, molecular modeling and biological evaluation of cinnamic acid derivatives with pyrazole moieties as novel anticancer agents’, RSC. Adv., 2014, 4, pp. 37197–37207, doi:10.1039/C4RA05257A.
  4. 4)
     • 28. Zare, M., Moradi-Shoeili, Z., Bagherzadeh, M., et al: ‘Immobilization of a molybdenum complex on the surface of magnetic nanoparticles for the catalytic epoxidation of olefins’, New. J. Chem., 2016, 40, pp. 1580–1586, doi:10.1039/C5NJ02218E.
  5. 5)
     • 46. Tan, T.T., White, E.: ‘Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells, in programmed cell death in cancer progression and therapy’, Springer. Adv. Exp. Med. Biol., 2008, 615, pp. 81–104, doi:10.1007/978-1-4020-6554-5_5.
  6. 6)
     • 17. Nossier, E., Somaia, S.A.E.-K., Nagy, M.A., et al: ‘Kinase inhibitory activities and molecular docking of a novel series of anticancer pyrazole derivatives’, Molecules., 2018, 23, p. 3074, doi:10.3390/molecules23123074.
  7. 7)
     • 41. Sever, B., Akalin-ciftci, G., Ozdemir, A., et al: ‘Design, synthesis and in vitro evaluation of new thiosemicarbazone derivatives as potential anticancer agents’, Marmara Pharm.J., 2019, 23, pp. 16–24.
  8. 8)
     • 59. Bai, J., Wang, R.-H., Qiao, Y., et al: ‘Schiff base derived from thiosemicarbazone and anthracene showed high potential in overcoming multidrug resistance in vitro with low drug resistance index’, Drug. Des. Devel. Ther., 2017, 11, pp. 2227–2237, doi:10.2147/DDDT.S138371.
  9. 9)
     • 48. Toton, E., Ignatowicz, E., Bernard, M., et al: ‘Evaluation of apoptotic activity of new condensed pyrazole derivatives’, J. Physiol. Pharmacol., 2013, 64, pp. 115–123.
  10. 10)
      • 52. Kang, R., Zhang, Q., Zeh, H.J., et al: ‘HMGB1 in cancer: good, bad, or both?’, J. Clin. Cancer. Res., 2013, 19, pp. 4046–4057, doi:10.1158/1078-0432.CCR-13-0495.
  11. 11)
      • 2. Liyanage, P.Y., Paulpandi, M., Ponraj, T., et al: ‘Nanoparticle-mediated targeted drug delivery for breast cancer treatment’, Biochim. Biophys. Acta, Rev. Cancer., 2019, 1871, pp. 419–433, doi:10.1016/j.bbcan.2019.04.006.
  12. 12)
      • 49. Su, Z., Yang, Z., Xu, Y., et al: ‘Apoptosis, autophagy, necroptosis, and cancer metastasis’, J. Mol. Cancer., 2015, 14, p. 48, doi:10.1186/s12943-015-0321-5.
  13. 13)
      • 40. Oliveira, P.F.d., Alves, J.M., Damascenoet, J.L., et al: ‘Cytotoxicity screening of essential oils in cancer cell lines’, Rev. Bras. Farmacogn., 2015, 25, pp. 183–188, doi:10.1016/j.bjp.2015.02.009.
  14. 14)
      • 25. Pfeffer, C., Singh, A.: ‘Apoptosis: a target for anticancer therapy’, Int. J. Mol. Sci., 2018, 19, p. 448, doi:10.3390/ijms19020448.
  15. 15)
      • 42. Habibi, A., Shandiz, S.A.S., Salehzadeh, A., et al: ‘Novel pyridinecarboxaldehyde thiosemicarbazone conjugated magnetite nanoparticulates (MNPs) promote apoptosis in human lung cancer A549 cells’, JBIC, J. Biol. Inorg. Chem., 2019, 25, pp. 1–10, doi:10.1007/s00775-019-01728-4.
  16. 16)
      • 39. Kadu, P.J., Kushareet, S.S., Thacker, D.D., et al: ‘Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS)’, Pharm. Dev. Technol., 2011, 16, pp. 65–74, doi:10.3109/10837450903499333.
  17. 17)
      • 4. Liu, D.C., Gao, M.J., Huo, Q., et al: ‘Design, synthesis, and apoptosis-promoting effect evaluation of novel pyrazole with benzo [d] thiazole derivatives containing aminoguanidine units’, J. Enzyme Inhib. Med. Chem., 2019, 34, pp. 829–837, doi:10.1080/14756366.2019.1591391.
  18. 18)
      • 26. Vinardell, M., Mitjans, M.: ‘Antitumor activities of metal oxide nanoparticles’, J Nanomaterials., 2015, 5, pp. 1004–1021, doi:10.3390/nano5021004.
  19. 19)
      • 5. Keter, F.K., Darkwa, J.: ‘Perspective: the potential of pyrazole-based compounds in medicine’, J. Biometals., 2012, 25, pp. 9–21, doi:10.1007/s10534-011-9496-4.
  20. 20)
      • 30. Faiyas, A.P.A., Vinod, E.M., Joseph, J., et al: ‘Dependence of pH and surfactant effect in the synthesis of magnetite (Fe3O4) nanoparticles and its properties’, J. Magn. Magn. Mater., 2010, 322, pp. 400–404, doi:10.1016/j.jmmm.2009.09.064.
  21. 21)
      • 20. Bhat, M.A., Al-Tahhan, M., Al-Omar, M.A., et al: ‘Design and synthesis of novel thiosemicarbazones as potent anti-breast cancer agents’, Lett. Drug Des. Discovery., 2019, 16, pp. 446–452, doi:10.2174/1570180815666181008100944.
  22. 22)
      • 6. Çalışkan, B., Yılmaz, A., Evren, I., et al: ‘Synthesis and evaluation of analgesic, anti-inflammatory, and anticancer activities of new pyrazole-3 (5)-carboxylic acid derivatives’, J. Med. Chem., 2013, 22, pp. 782–793, doi:10.1007/s00044-012-0072-4.
  23. 23)
      • 21. Scott, M.: ‘Cancer: A twist in a hedgehog's tale’, J. Nature., 2003, 425, pp. 781–782, doi:10.1038/425780a.
  24. 24)
      • 56. Reddy, T.S., Kulhari, H., Reddy, V.G., et al: ‘Design, synthesis and biological evaluation of 1, 3-diphenyl-1H-pyrazole derivatives containing benzimidazole skeleton as potential anticancer and apoptosis inducing agents’, Eur. J. Med. Chem., 2015, 101, pp. 790–805, doi:10.1016/j.ejmech.2015.07.031.
  25. 25)
      • 36. Wiles, D., Gingras, B., Suprunchuk, T.: ‘The C = S stretching vibration in the infrared spectra of some thiosemicarbazones’, Can. J. Chem., 1967, 45, pp. 469–473, doi:10.1139/v67-081.
  26. 26)
      • 23. Kouassi, G.K., Irudayaraj, J.: ‘A nanoparticle-based immobilization assay for prion-kinetics study’, J. Nanobiotechnology., 2006, 4, p. 8, doi:10.1186/1477-3155-4-8.
  27. 27)
      • 55. Kim, C.H., Han, S.I., Lee, S.Y., et al: ‘Protein kinase C-ERK1/2 signal pathway switches glucose depletion-induced necrosis to apoptosis by regulating superoxide dismutases and suppressing reactive oxygen species production in A549 lung cancer cells’, J Cell Physiol., 2007, 211, pp. 371–385, doi:10.1002/jcp.20941.
  28. 28)
      • 33. Moradi-Shoeili, Z., Zare, M., Bagherzadeh, M.: ‘Synthesis and characterization of magnetic silica-supported Mn (II)-substituted polyoxophosphotungstate as catalyst in sulfoxidation reaction’, J Nanopart Res., 2016, 18, p. 298, doi:10.1007/s11051-016-3609-5.
  29. 29)
      • 57. Ghavami, S., Hashemi, M., Ande, S.R., et al: ‘Apoptosis and cancer: mutations within caspase genes’, J. Med. Genet., 2009, 46, pp. 497–510, doi:10.1136/jmg.2009.066944.
  30. 30)
      • 43. Czarnomysy, R., Surażyński, A., Muszynska, A., et al: ‘A novel series of pyrazole-platinum (II) complexes as potential anti-cancer agents that induce cell cycle arrest and apoptosis in breast cancer cells’, J Enzyme Inhib Med Chem., 2018, 33, pp. 1006–1023, doi:10.1080/14756366.2018.1471687.
  31. 31)
      • 45. Fulda, S., Debatin, K.M.: ‘Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy’, J Oncogene., 2006, 25, pp. 4798–4811, doi:10.1038/sj.onc.1209608.
  32. 32)
      • 58. Yassaee, V.R., Zeinali, S., Harirchi, I., et al: ‘Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer’, Breast. Cancer. Res, 2002, 4, p. R6, doi:10.1186/bcr443.
  33. 33)
      • 24. Lin, B.-L., Shen, X.-D., Cui, S.: ‘Application of nanosized Fe3O4 in anticancer drug carriers with target-orientation and sustained-release properties’, J. Biomed. Mater., 2007, 2, p. 132.
  34. 34)
      • 53. Barreiro-Alonso, A., Lamas-Maceiras, M., Rodríguez-Belmonte, E., et al: ‘High mobility group B proteins, their partners, and other redox sensors in ovarian and prostate cancer’, J. Oxid. Med. Cell Longev., 2016, 2016, pp. 1–17, doi:10.1155/2016/5845061.
  35. 35)
      • 50. Frisch, S.M., Schaller, M., Cieply, B.: ‘Mechanisms that link the oncogenic epithelial–mesenchymal transition to suppression of anoikis’, J. Cell. Sci., 2013, 126, pp. 21–29, doi:10.1242/jcs.120907.
  36. 36)
      • 27. Wang, J., Sui, M., Fan, W.: ‘Nanoparticles for tumor targeted therapies and their pharmacokinetics’, Curr. Drug Metab., 2010, 11, pp. 129–141, doi:10.2174/138920010791110827.
  37. 37)
      • 38. Sallem, F., Haji, R., Vervandier-Fasseur, D., et al: ‘Elaboration of trans-resveratrol derivative-loaded superparamagnetic iron oxide nanoparticles for glioma treatment’, Nanomaterials., 2019, 9, pp. 287–307, doi:10.3390/nano9020287.
  38. 38)
      • 47. Mohamed, M.F., Mohamed, M.S., Fathi, M.M., et al: ‘Chalcones incorporated pyrazole ring inhibit proliferation, cell cycle progression, angiogenesis and induce apoptosis of MCF7 cell line’, Anti-Cancer. Agents. Med. Chem., 2014, 14, pp. 1282–1292.
  39. 39)
      • 13. Nitulescu, G.M., Olaru, O.T., Nedelcu, G.: ‘In the search of Aurora-A kinase inhibitors as antitumor agents’, Rom. J. Biophys., 2014, 24, pp. 243–254.
  40. 40)
      • 14. Nitulescu, G., Matei, L., Aldea, I.M., et al: ‘Ultrasound-assisted synthesis and anticancer evaluation of new pyrazole derivatives as cell cycle inhibitors’, Arabian J. Chem., 2019, 12, pp. 816–824, doi:10.1016/j.arabjc.2015.12.006.
  41. 41)
      • 20. Yadav, P., Varadavenkatesan, T., Selvaraj, R.: ‘Antibacterial and dye degradation potential of zero-valent silver nanoparticles synthesised using the leaf extract of Spondias dulcis’, IET Nanobiotechnol., 2019, 13, pp. 84–89 (doi: 10.1049/iet-nbt.2018.5058).
  42. 42)
      • 8. Pevarello, P., Brasca, M.G., Orsini, P., et al: ‘3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization’, J. Med. Chem., 2005, 48, pp. 2944–2956, doi:10.1021/jm0408870.
  43. 43)
      • 1. Ebrahimnezhad, Z., Zarghami, N., Keyhani, M., et al: ‘Inhibition of hTERT gene expression by silibinin-loaded PLGA-PEG-Fe3O4 in T47D breast cancer cell line’, J. Bioimpacts., 2013, 3, p. 67, doi:10.5681/bi.2013.005.
  44. 44)
      • 29. Ahn, T., Kim, H.K., Yang, H.M., et al: ‘Formation pathways of magnetite nanoparticles by coprecipitation method’, J. Phys. Chem. C., 2012, 116, pp. 6069–6076, doi:10.1021/jp211843g.
  45. 45)
      • 7. Howard, S., Berdini, V., Boulstridge, J.A., et al: ‘Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity’, J. Med. Chem., 2008, 52, pp. 379–388, doi:10.1021/jm800984v.
  46. 46)
      • 19. ElMajzoub, R., Fayyad-kazan, M., ElDine, A.N., et al: ‘A thiosemicarbazone derivative induces triple negative breast cancer cell apoptosis: possible role of miRNA-125a-5p and miRNA-181a-5p’, Genes. Genomics., 2019, 41, pp. 1431–1443, doi:10.1007/s13258-019-00866-y.
  47. 47)
      • 3. Kavithaa, K., Paulpandi, M., Ponraj, T., et al: ‘Induction of intrinsic apoptotic pathway in human breast cancer (MCF-7) cells through facile biosynthesized zinc oxide nanorods’, Karbala Int. J. Mod. Sci., 2016, 2, pp. 46–55, doi:10.1016/j.kijoms.2016.01.002.
  48. 48)
      • 16. Plé, P.A., Jung, F., Ashton, S., et al: ‘Discovery of AZD2932, a new quinazoline ether inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg’, Med. Chem. Lett., 2012, 22, pp. 262–266, doi:10.1016/j.bmcl.2011.11.019.
  49. 49)
      • 31. Peña-Morán, O., Villarreal, M., Álvarez-Berber, L., et al: ‘Cytotoxicity, post-treatment recovery, and selectivity analysis of naturally occurring podophyllotoxins from Bursera fagaroides var. fagaroides on breast cancer cell lines’, Molecules., 2016, 21, p. 1013, doi:10.3390/molecules21081013.
  50. 50)
      • 22. Gokhale, N., Padhye, S., Newton, C., et al: ‘Hydroxynaphthoquinone metal complexes as antitumor agents x: synthesis, structure, spectroscopy and in vitro antitumor activity of 3-methyl-phenylazo lawsone derivatives and their metal complexes against human breast cancer cell line mcf-7’, J. Metal-Based. Drugs., 2000, 7, pp. 121–128, doi:10.1155/MBD.2000.121.
  51. 51)
      • 51. Knaul, F.M., Nigenda, G., Lozano, R., et al: ‘Cáncer de mama en México: una prioridad apremiante’, SciELO., 2009, 51, pp. 335–344.
  52. 52)
      • 18. Abou-Hussen, A., El-Metwally, N., Saad, E., et al: ‘Spectral, magnetic, thermal and electrochemical studies on phthaloyl bis (thiosemicarbazide) complexes’, J. Coord. Chem., 2005, 58, pp. 1735–1749, doi:10.1080/00958970500262270.
  53. 53)
      • 10. Bebbington, D., Binch, H., Charrier, J.D., et al: ‘The discovery of the potent aurora inhibitor MK-0457 (VX-680)’, J Bioorganic Med. Chem. Lett., 2009, 19, pp. 3586–3592, doi:10.1016/j.bmcl.2009.04.136.
  54. 54)
      • 54. Ding, J., Cui, X., Liu, Q., et al: ‘Emerging role of HMGB1 in lung diseases: friend or foe’, J. Cell Mol. Med., 2017, 21, pp. 1046–1057, doi:10.1111/jcmm.13048.
  55. 55)
      • 11. Liu, Y., Zhu, X.: ‘Endoplasmic reticulum-mitochondria tethering in neurodegenerative diseases’, J. Transl. Neurodegener., 2017, 6, p. 21, doi:10.1186/s40035-017-0092-6.
  56. 56)
      • 12. Villa-Pulgarín, J.A., Gajate, C., Botet, J., et al: ‘Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine’, J. PLoS. Negl. Trop. Dis., 2017, 11, pp. 1–31, doi:10.1371/journal.pntd.0005805.
  57. 57)
      • 35. Patil, R., Delekar, S., Mane, D., et al: ‘Synthesis, structural and magnetic properties of different metal ion substituted nanocrystalline zinc ferrite’, J. Results. in Physics., 2013, 3, pp. 129–133, doi:10.1016/j.rinp.2013.08.002.
  58. 58)
      • 44. Lee, S.Y., Ju, M.K., Jeon, H.M., et al: ‘Regulation of tumor progression by programmed necrosis’, J. Oxid. Med. Cell. Longev., 2018, 1, pp. 1–28, doi:10.1155/2018/3537471.
  59. 59)
      • 9. Chahrour, O., Cairns, D., Omran, Z.: ‘Small molecule kinase inhibitors as anti-cancer therapeutics’, J. Mini. Rev. Med. Chem., 2012, 12, pp. 399–411, doi:10.2174/138955712800493915.